ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!ONCR Company Profile and Key Details
Oncorus, Inc.
ONCR Stock Price Chart
Stock Price Today
Oncorus, Inc. (ONCR) stock declined over -3.08%, trading at $0.13 on NASDAQ, down from the previous close of $0.13. The stock opened at $0.13, fluctuating between $0.13 and $0.20 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 64 |
| Beta | 1.95 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Oncorus, Inc. (NASDAQ: ONCR) stock price is $0.13 in the last trading session. During the trading session, ONCR stock reached the peak price of $0.20 while $0.13 was the lowest point it dropped to. The percentage change in ONCR stock occurred in the recent session was -3.08% while the dollar amount for the price change in ONCR stock was -$0.00.
The NASDAQ listed ONCR is part of Biotechnology industry that operates in the broader Healthcare sector. Oncorus, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Mitchell H. Finer Ph.D.
Non-Executive Director
Dr. John Mayer Goldberg M.D.
Chief Medical Officer
Chris German
Controller
Brian J. Shea
Director of Legal Counsel & Corporation Sec.
Mr. Richard J. Wanstall M.B.A.
Chief Financial Officer, Chief Accounting Officer & Treasurer
Dr. Theodore T. Ashburn M.D., Ph.D.
Pres, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer & Director
Mr. Stephen W. Harbin
Chief Operating Officer & Chief of Staff
Mr. Brian J. Shea
Pres, Interim Chief Executive Officer, Gen. Counsel & Corporation Sec.
Mr. Craig R. Jalbert CIRA
Pres, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director
ONCR's closing price is 1,160% higher than its 52-week low of $0.01 where as its distance from 52-week high of $0.47 is -73.19%.
Number of ONCR employees currently stands at 64.
Official Website of ONCR is: https://www.oncorus.com
ONCR could be contacted at phone 857 320 6400 and can also be accessed through its website. ONCR operates from 50 Hampshire Street, Cambridge, MA 02139, United States.
ONCR stock volume for the day was 135.95K shares. The average number of ONCR shares traded daily for last 3 months was 108.68K.
The market value of ONCR currently stands at $0.00 with its latest stock price at $0.13 and 0 of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com